Summary
Aurobindo Pharma's subsidiary, Eugia Pharma, received a warning letter from the USFDA following an inspection of its Telangana formulation manufacturing facility, which concluded with four observations. The company stated that existing US market supplies remain unaffected and reaffirmed its commitment to US FDA compliance.